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Abstract 
 Huntington’s is a genetic neurodegenerative disease with dominant 
autosomal transmission, and high penetrance. This transmission model 
represents a high recurrence risk (50%) in case of the descendants of affected 
individuals. This disease can have its debut during adulthood, 40-50 years 
old or, in case of its juvenile form, during childhood or adolescence. The 
disease evolves with dystonia, choric movements, rigidity and dementia. 
Genetic testing for HD mutation is performed through molecular techniques 
and is possible at any age, independent of whether the person is symptomatic 
or asymptomatic. The genetic testing allows the identification of those 
individuals who are carriers of mutations on certain genes, these mutations 
being the underlying cause for some genetic diseases. At the present moment 
there are 3 types of genetic testing: diagnostic, carrier and predictive. The 
predictive tests identify whether an individual is a carrier for a certain 
specific genetic mutation and whether the possibility exists for him to 
develop certain health issues later on.  Being aware of the carrier status for a 
certain genetic mutation for Huntington’s represents an element with major 
impact on the individual and on their family and can lead to discrimination 
from the side of the insurance companies, employers as well as others.  
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Introduction 
 Huntington’s disease is a rare genetic malady, neurodegenerative, 
which presents with a prevalence of 5-10 cases at 100.000 people among the 
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Caucasian population (Bates, 2002). This disease usually has its debut at 
middle age, after 35-40 years, and has a slow progression. In general, after 5 
to 10 years from its onset most of the patients are significantly affected and 
only a small part of the diagnosed individuals are capable of working a stable 
job after this period of time.  
 In terms of genetics, Huntington’s disease is inherited in an 
autosomal dominant manner, meaning that individuals that have one affected 
parent have 50% chances of inheriting the mutant gene and developing the 
disease at one point in their lives. The risk depends on the age of the 
individual and the length of the CAG sequence taken into consideration. 
Therefore, a 25 year old person with an affected parent will have 7.5% risk 
of developing HD during the next 10 years and 21% risk during the next 20 
years (Harper, 1992).Changes in the sequence that determine the 
pathological phenotype are found on exon 1 of the gene where the triple 
nucleotide CAG can be found. The gene to which the mutations responsible 
for Huntington’s belong is localized on chromosome 4p16.3. While the gene 
is transmitted from generation to generation the length of the trinucleotide 
increases. If the onset of Huntington’s disease manifests during adulthood, 
the individual would present on the HTT gene around 40-50 repetitive CAG 
trinucleotides, while persons who have the disease since childhood or 
adolescence have over 60 CAG nucleotides. Normally the CAG segment is 
only repeated 10 to 35 times. In the case of HD patients the CAG segment 
appears for 36-120 times. In case of individuals who present only 36 to 39 
repetitive CAG they could or could not manifest signs and symptoms for 
Huntington’s, in comparison to those with over 40 repetitive units in the 
sequence who will develop the disease.  
 In case of Huntington’s the ways to determine the genetic mutation 
have been known since 1993, leading to a predictive genetic test with a 
100% sensitivity and specificity (Meiser, 2000). A specific feature for 
Huntington’s is the ‘’genetic anticipation’’ phenomenon, meaning that 
symptoms which should appear at younger ages, during childhood or 
adolescence, have a greater severity when transmitted throughout 
generations. It was proven that genetic anticipation is caused by the 
instability of the repetitive trinucleotide sequence CAG throughout 
generations. Together with the transgenerational transmission of the 
sequence, the number of trinucleotide sequences increases, leading to the 
juvenile onset which presents with a worsened evolution than the one with 
adult onset.  
 It was proven that there is an inverse relation between age of onset 
for HD and the length of the CAG sequence (The Huntington’s Disease 
Collaborative Research Group, 1993). 
European Scientific Journal October 2015 edition vol.11, No.30 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
3 
 Although the CAG sequence presents both with instability and 
variability, these are not independent from maternal or paternal inheritance. 
Studies have shown that these expansions are more frequent in case of 
paternal inheritance (Duyao,1993).The fact that longer CAG sequences tend 
to appear in case of the inheritance on a paternal line, and adding the fact that 
the age of onset is in an inverse relation with the length of the CAG 
sequence, offers an explanation of the fact that 75% of the patients with 
juvenile Huntington’s disease inherit the gene from their fathers (Ranen , 
1995). 
 In 2011, in the Human Genetics Commission Report on the concept 
of Genetic Discrimination, it was stated that: together with the new genetic 
sequencing techniques of the human genome and with the reduced costs for 
genetic testing, the possibility will exist that genetics will be used for new 
purposes that will not be easy to predict (Modell, 2002). 
 There are 3 types of genetic testing: diagnostic, carrier and predictive. 
a) Diagnostic genetic testing: identify the current status of the 
individuals. The most well-known test are the prenatal screening tests and 
screening tests applied on newborns.  
b) Genetic testing for carriers: used in order to identify individuals with 
genetic conditions. 
c) Predictive genetic testing: give information on the fact that a person 
presents with a certain genetic mutation which in time leads to the 
development of a certain condition. The test is used in the case of healthy 
individuals who have a medical history for a certain conditions but do not 
present with symptoms.  
 The most frequent diseases that get tested using predictive tests are: 
Huntington’s disease, breast cancer, Down syndrome, cystic fibrosis and 
phenylketonuria (Human Genetics Commission-Report on The Concept of 
Genetic Discrimination, 2011). 
 Candidates for predictive testing are asymptomatic persons, who 
want to find out if they are susceptible to developing a genetic condition in 
the future. The information has personal value but, in addition to that it 
affects the family members. The potential for genetic discrimination – 
especially in the case of medical insurance, life insurance and employment – 
represents a major concern for patients in predictive testing programs. 
 Genetic discrimination is defined as difference in attitude towards the 
individual in regard to rights, privileges and opportunities, based only on 
genetic information, including a medical history (Billings, 1992).Introducing 
predictive genetic testing has certain consequences such as social, political, 
economic and psychological. In regard to this aspect the following should be 
taken into account: a) Firstly, genetic information is family related, and the 
test results for one individual have direct health implications for other 
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genetically related persons; b) Secondly, the risks of genetic testing cannot 
be obvious as they are psychological, social and financial risks. The 
psychosocial risks include feelings like guilt, anxiety, self-respect, social 
stigma, and discrimination in regard to insurance and employment. c) 
Thirdly, genetic information often has a limited predictive power. 
 An example for genetic discrimination in case of patients with risk 
for developing Huntington’s disease is that of a young teacher in Germany, 
who was refused the employment in a school because some of her family 
members had HD, therefore she presented with a 50% risk of developing the 
condition later on in life. The examining physician reported her employable 
but she also presented with a higher risk for absenteeism in the future 
(Burgermeister, 2003). 
 Another example is that of a social worker in the United States of 
America, who was working for an agency carrying for chronic patients. 
During a workshop on the topic of care in case of disabled patients, she told 
a story of the first person she ever cared for – her mother that died because of 
Huntington’s. The fact that her mother had Huntington’s suggested that she 
presented with a 50% risk for developing this condition, for which reason 
after one week from making this statement the company that used to hire her 
a social worker, terminated her employment contract 
(http://www.geneticalliance.org/advocacy/policyissues/geneticdiscrimination
) 
 The recent case of the teacher in Germany who was refused a job 
because she presented with a high risk for HD (Burgermeister, 2003) and 
that of the social worker who got her employment contract terminated, rise 
the concern in regard to discrimination by employers based on genetic 
testing. This attitude introduces additional ethical considerations. 
 It is right to deny access to a work place based on predictive genetic 
information from a genetic test or from other source or based on a family 
history of a certain disorder? That question (and a similar one regarding 
private health insurances) have been on the public agenda for 20 years and 
have been debated upon at large on both international and European level, in 
the USA and in other parts of the world. 
 There are three main reasons for which using genetic information in 
the employment framework is so controversial. Firstly, in the nowadays 
society, to be employed is a crucial fact when it comes to income, social rank 
and social safety; selection of personnel based on genetic criteria can easily 
lead to social exclusion for large groups of people because of dubious 
reasons – ‘’a genetic subclass’’. Secondly, collecting genetic information 
deals with the right for a private life, especially when workers are requested 
a genetic testing. Thirdly, being aware of the fact that knowledge regarding 
future health risks can have a negative impact on a person’s work place or 
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insurance opportunities, discouraging people from taking these genetic tests, 
deterring from the health benefits they, their relatives, and children could 
have from these test (Feldman ,2011). 
 The European Council established a Convention for Human Rights 
and Biomedicine (1996), in order to cope with genetic discrimination 
(Lemmens, 2000) which provides that genetic testing can only be carried out 
for medical purposes or for scientific research related to medical purposes, 
and not for selective purposes for activity and insurance. The most recent 
moratorium regarding genetic testing in Great Britain (Secretary of State for 
Health, 2003) protects against insurance related discrimination for those with 
risk for HD. 
 In May 2008, the US Congress voted an act known as the Genetic 
Information Non-Discrimination Act (GINA) that enacts and gives 
protection for persons in regard to genetic discrimination, through the 
regulation of genetic information usage upon employment, in the work place 
or in the health insurance sector (Office for Human Research Protections 
(OHRP) 2009). 
 There are people in Canada with a family history of HD who were 
refused life insurance coverage and were informed that they could be subject 
to predictive genetic testing in order to qualify for insurance 
(Lemmens,2000). Such a constraint threatens basic autonomy, including 
intimacy and confidentiality rights. In this manner, people are bound to 
obtain information that they maybe would not want to know, and the 
potential adverse reactions that could appear (depression, psychiatric 
admission, suicide attempts)(Almqvist, 2003)are significant. In the case of 
persons with Huntington’s, suicide in more frequently present in the general 
population and is the third most common cause of death(Ranen ,1995). 
 In Australia, from 2002 until 2005 was carried out the Australian 
Project for Genetic Discrimination, with the purpose of gathering 
information regarding genetic discrimination in the case of individuals with 
risk for HD or that could develop the disease (Otlowski, 2002; Taylor ,2007). 
 The results of this study presented with similar discrimination cases 
in case of healthy individuals, which appeared because of health services, 
employers and insurance companies. Furthermore, within this study the 
person with Huntington’s reported discrimination actions or social 
stigmatization from the aforementioned institutions (Taylor, 2008). 
 Studies were carried out that presented many genetic discrimination 
cases when it came to people with HD. A couple was refused application for 
adoption because they presented with a high risk for Huntington’s (Billings, 
1992). 
 In a study carried out by Bombard et al in Canada, on 233 
asymptomatic persons, genetically tested for high risk for Huntington’s, a 
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40% of the people reported a risen concern regarding genetic discrimination 
(Bombard , 2009). 
 In North America, in a study carried out on 1001 individuals with 
risk for Huntington’s, these people reported that their biggest concern was 
losing their health insurance, and from this reason alone 41.6% pay for the 
test or other medical services themselves, trying to hide from the employer 
or insurer their risk for HD (Oster, 2008). 
 The sole ability of looking at someone’s future through predictive 
genetic testing brings with it the potential of personal and family 
overthrowing. The majority of the people choose not to obtain this 
information; at world level the absorption for genetic testing is low, from 5% 
to 24% in case of persons with risk (Creighton, 2003). It is a personal and 
complicated decision. With this aim, numerous protocols were developed in 
order to explore the pro and con arguments for the candidates for genetic 
testing. Most of the people experiment a significant increase in psychological 
stress levels, no matter whether they are proven to have a high or low risk for 
developing HD (Almqvist,2003). 
 Numerous protocols and international guidelines were published, 
conceived by members of scientific groups such as: International Huntington 
Association (IHA) and Working Group on Huntington disease of the World 
Federation of Neurology (WFN), which assure that people with a high risk 
for Huntington’s understand and accept the implications of this diagnosis. 
  
Conclusion: 
 Lack of policy decisions and educational campaigns meant to inform 
the population regarding Huntington’s disease, led to discriminative 
practices from the employers and insurance companies to individuals 
diagnosed with this disease or being at risk for developing it. 
Furthermore, there is an urgent need for prioritization of efforts for 
legislative improvement of the medical services addressed to individuals 
with Huntington, such as: 
1. Ensuring patients’ access to quality health care, including diagnosis 
through genetic tests and appropriate treatments; 
2. Involvement and participation of the patients and their representatives 
in developing health policies; 
3. Promotion and involvement of patients’ activities in population  
educational activities about this disorder; 
4. Achievement of National Program for familial screening regarding 
early detection of individuals at risk of developing Huntington’s disease.   
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